newsfilter
← Earnings
Earnings Releases·

Septerna — Third Quarter 2026 Earnings Summary

Septerna reported a net loss of $26.6 million for the third quarter ended September 30, 2026, with total revenue of $18.9 million driven by collaboration activities with Novo Nordisk. The company maintains a cash position of $565.2 million, which is projected to fund operations through mid-2029. Pipeline progress includes an ongoing Phase 1 trial for the oral PTH1R agonist SEP-479, with data expected in early 2027, and plans to initiate a Phase 1 trial for the newly selected TSHR NAM candidate SEP-204 in the first quarter of 2027.

Company
SEPTERNA INC
Sector
Healthcare
Industry
Biotechnology